Back to Journals » Clinical Interventions in Aging » Biomarker-Guided Clinical Interventions in Geriatric Heart Failure: From Phenotyping to Practice
Clinical Interventions in Aging
- View all (3280)
- Volume 21, 2026 (89)
- Volume 20, 2025 (216)
- Volume 19, 2024 (206)
- Volume 18, 2023 (185)
- Volume 17, 2022 (166)
- Volume 16, 2021 (190)
- Volume 15, 2020 (237)
- Volume 14, 2019 (225)
- Volume 13, 2018 (262)
- Volume 12, 2017 (232)
- Volume 11, 2016 (210)
- Volume 10, 2015 (220)
- Volume 9, 2014 (242)
- Volume 8, 2013 (190)
- Volume 7, 2012 (68)
- Volume 6, 2011 (39)
- Volume 5, 2010 (49)
- Volume 4, 2009 (50)
- Volume 3, 2008 (74)
- Volume 2, 2007 (77)
- Volume 1, 2006 (53)
Journal Articles:
- Understanding Physical Functioning in Older Adults – New Approaches and Novel Interventions (5)
- Innovative Care Models for Older Adults: The Role of Telehealth and Emerging Technologies (2)
- Perioperative Management and Integrated Surgical Care for Older Adults (5)
- Hormone Replacement Therapy in Aging - Benefits, Risks, and Clinical Considerations for Older Adults (1)
- Tech for Tomorrow: Advancing Quality of Life for People with Dementia (1)
- Falls, Fall Injuries, and their Prevention among Community-Dwelling Older Adults (7)
- The Art of Aging Well: The Role of Creative Arts in Modulating Cognitive Functioning and Well-Being in Aging (1)
- Nutrition in Aging (1)
- Innovative approaches to aging care: from home and beyond (13)
- Promoting Physical Activity Participation as a Strategy for Protecting the Health of Older Adults in a Changing Climate (1)
- Masters Athletics: Lessons for physical interventions in aging (3)
- Dealing with dementia: prioritizing high-quality dementia care (7)
- A personal hourglass: chronobiology in aging (1)
Biomarker-Guided Clinical Interventions in Geriatric Heart Failure: From Phenotyping to Practice
Heart failure (HF) affects over 64 million people worldwide and disproportionately burdens adults aged 65 and above, in whom clinical presentation, comorbidity burden, and physiological reserve differ markedly from younger patients. In this population, guideline-directed medical therapies — including renin-angiotensin-aldosterone system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — produce variable effects on biomarkers of inflammation, neurohormonal activation, and cardiorenal stress, with evidence specific to older adults remaining limited. This Article Collection invites original research, systematic reviews, and narrative reviews examining how clinical interventions in older adults with HF influence biomarker profiles, phenotypic trajectories, and patient outcomes.